Table 1.
The frequency of common molecular alterations in pan-cancer based on the data from MSK-IMPACT sequencing(%).
| N |
EGFR mutation |
EGFR amplification |
ROS1 fusion |
BRAF mutation |
Her-2 amplification |
Her-2 mutation |
PIK3CA mutation |
CDK4 amplification |
CDK6 amplification |
Met amplification |
BRCA1/2 mutation |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NSCLC | 1, 668 | 18.65 | 1.68 | 1.62 | 5.16 | 21.7 | 3.23 | 6.89 | 3.84 | 0.3 | 2.1 | 5.22 |
| Breast cancer | 1, 324 | 1.36 | 1.44 | 0 | 0.3 | 13.22 | 3.63 | 34.59 | 1.44 | 0.3 | 0.15 | 5.29 |
| Colorectal cancer | 1, 007 | 2.09 | 1.29 | 0 | 11.52 | 2.38 | 3.87 | 19.17 | 0 | 0.3 | 1.19 | 8.54 |
| Prostate | 717 | 0.56 | 0.42 | 0 | 1.67 | 0 | 0.98 | 3.35 | 0.7 | 0.42 | 0.14 | 5.58 |
| Pancreatic cancer | 502 | 0.8 | 0.2 | 0.2 | 2.39 | 1.2 | 0.6 | 3.39 | 0 | 0.8 | 0 | 3.07 |
| Soft tissue sarcoma | 443 | 0.9 | 0.9 | 0.45 | 1.35 | 0 | 0.68 | 3.84 | 17.16 | 0.68 | 1.35 | 2.15 |
| Bladder cancer | 423 | 4.49 | 1.65 | 0.24 | 3.78 | 4.49 | 10.87 | 22.93 | 1.42 | 0.24 | 0.24 | 14.66 |
| Melanoma | 365 | 6.58 | 0.55 | 0 | 30.41 | 1.1 | 3.01 | 4.11 | 3.29 | 0.82 | 1.64 | 12.6 |
| Renal cell carcinoma | 361 | 1.11 | 0 | 0 | 0 | 0 | 1.66 | 3.88 | 0 | 0 | 1.66 | 1.11 |
| Hepatobiliary cancer | 355 | 1.13 | 1.41 | 0 | 3.1 | 2.54 | 0.56 | 3.94 | 0.85 | 1.13 | 0.56 | 2.25 |
| Esophagogastric cancer | 341 | 0 | 0 | 0.29 | 1.47 | 0 | 0 | 7.04 | 1.17 | 3.81 | 2.64 | 5.28 |
| Thyroid cancer | 231 | 0 | 0 | 0 | 38.1 | 0 | 0.43 | 6.06 | 0.43 | 0 | 0 | 1.73 |
| Ovarian cancer | 224 | 0.45 | 0 | 0.89 | 1.34 | 3.57 | 1.34 | 10.27 | 0.89 | 0 | 0.89 | 3.13 |
| Endometrial cancer | 218 | 4.13 | 0 | 0 | 4.13 | 7.34 | 4.59 | 40.37 | 0.46 | 0 | 0 | 7.63 |
| Head and neck caner | 186 | 2.15 | 6.99 | 0 | 0.54 | 2.69 | 1.08 | 19.35 | 0.54 | 1.61 | 0 | 5.38 |
| Cancer of unknown primary | 186 | 3.23 | 2.69 | 0.54 | 5.91 | 4.3 | 3.76 | 9.14 | 1.61 | 0.54 | 0.54 | 5.46 |